目的分析终末期肝病模型(model for end-stage liver disease,MELD)评估我国慢性乙型重型肝炎患者预后的临床价值。方法回顾性分析2006年1月至2008年12月5家医院收治的慢性乙型重型肝炎住院患者561例临床资料,分为生存组和死亡组,计算...目的分析终末期肝病模型(model for end-stage liver disease,MELD)评估我国慢性乙型重型肝炎患者预后的临床价值。方法回顾性分析2006年1月至2008年12月5家医院收治的慢性乙型重型肝炎住院患者561例临床资料,分为生存组和死亡组,计算患者入院时的MELD评分,应用t’检验、Logistic回归分析、受试者工作特征(receiver operating characteristic curve,ROC)曲线下面积(area under curve,AUC)评价MELD对慢性乙型重型肝炎预后的预测价值。结果生存组的MELD分值为(22.25±4.35),死亡组MELD分值为(28.94±8.76),差异有统计学意义(P<0.01)。Logistic回归分析表明,在其他影响因素均衡的条件下,MELD分值每增加1,死亡的可能性增加至1.182倍,MELD评分的Logistic回归方程预测预后总的正确率为68.4%,且差异有统计学意义(P<0.01);MELD评分的AUC为0.759,95%置信区间为(0.720~0.798),MELD界值为27,其诊断的正确度为中等。结论 MELD评分系统预测我国慢性乙型重型肝炎患者的预后有临床应用价值,但效能中等。展开更多
Objective: To evaluate the efficacy and safety of Chinese medicine(CM) plus Western medicine(WM) in the treatment of pediatric patients with severe hand, foot and mouth disease(HFMD) by conducting a prospective, contr...Objective: To evaluate the efficacy and safety of Chinese medicine(CM) plus Western medicine(WM) in the treatment of pediatric patients with severe hand, foot and mouth disease(HFMD) by conducting a prospective, controlled, and randomized trial. Methods: A total of 451 pediatric patients with severe HFMD were randomly assigned to receive WM therapy alone(224 cases, WM therapy group) or CM [Reduning Injection(热毒宁注射液) or Xiyanping Injection(喜炎平注射液)] plus WM therapy(227 cases, CM plus WM therapy group) for 7–10 days, according to a web-based randomization system. The primary outcome was fever clearance time, which was presented as temperature decreased half-life time. The secondary outcomes included the rate of rash/herpes disappearance within 120 h, as well as the rate for cough, runny nose, lethargy and weakness, agitation or irritability, and vomiting clearance within 120 h. The drug-related adverse events were also recorded. Results: The temperature decreased half-life time was 40.4 h in the WM therapy group, significantly longer than 27.2 h in the CM plus WM therapy group(P<0.01). Moreover, the rate for rash/herpes disappearance within 120 h was 43.6%(99/227) in the CM plus WM therapy group, significantly higher than 29.5%(66/224) in the WM therapy group(P<0.01). In addition, the rate for cough, lethargy and weakness, agitation or irritability disappearance within 120 h was 32.6%(74/227) in the CM plus WM therapy group, significantly higher than 19.2%(43/224) in the WM therapy group(P<0.01). No drug-related adverse events were observed during the course of the study. Conclusions: The combined CM and WM therapy achieved a better therapeutic efficacy in treating severe HFMD than the WM therapy alone. Reduning or Xiyanping Injections may become an important complementary therapy to WM for relieving the symptoms of severe HFMD.展开更多
基金Supported by the Research Project of State Administration of Traditional Chinese Medicine,China(No.200907001-3)
文摘Objective: To evaluate the efficacy and safety of Chinese medicine(CM) plus Western medicine(WM) in the treatment of pediatric patients with severe hand, foot and mouth disease(HFMD) by conducting a prospective, controlled, and randomized trial. Methods: A total of 451 pediatric patients with severe HFMD were randomly assigned to receive WM therapy alone(224 cases, WM therapy group) or CM [Reduning Injection(热毒宁注射液) or Xiyanping Injection(喜炎平注射液)] plus WM therapy(227 cases, CM plus WM therapy group) for 7–10 days, according to a web-based randomization system. The primary outcome was fever clearance time, which was presented as temperature decreased half-life time. The secondary outcomes included the rate of rash/herpes disappearance within 120 h, as well as the rate for cough, runny nose, lethargy and weakness, agitation or irritability, and vomiting clearance within 120 h. The drug-related adverse events were also recorded. Results: The temperature decreased half-life time was 40.4 h in the WM therapy group, significantly longer than 27.2 h in the CM plus WM therapy group(P<0.01). Moreover, the rate for rash/herpes disappearance within 120 h was 43.6%(99/227) in the CM plus WM therapy group, significantly higher than 29.5%(66/224) in the WM therapy group(P<0.01). In addition, the rate for cough, lethargy and weakness, agitation or irritability disappearance within 120 h was 32.6%(74/227) in the CM plus WM therapy group, significantly higher than 19.2%(43/224) in the WM therapy group(P<0.01). No drug-related adverse events were observed during the course of the study. Conclusions: The combined CM and WM therapy achieved a better therapeutic efficacy in treating severe HFMD than the WM therapy alone. Reduning or Xiyanping Injections may become an important complementary therapy to WM for relieving the symptoms of severe HFMD.